Abstract
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG).
Methods We conducted a double-blind randomized controlled phase 1 clinical trial to evaluate the safety and immunogenicity of BBV152. A total of 375 participants were randomized equally to receive three vaccine formulations (n=100 each) prepared with 3 μg with Algel-IMDG, 6 μg with Algel-IMDG, and 6 μg with Algel, and an Algel only control arm (n=75). Vaccines were administered on a two-dose intramuscular accelerated schedule on day 0 (baseline) and day 14. The primary outcomes were reactogenicity and safety. The secondary outcomes were immunogenicity based on the anti-IgG S1 response (detected with an enzyme-linked immunosorbent assay [ELISA] and wild-type virus neutralization [microneutralization and plaque reduction neutralization assays]). Cell-mediated responses were also evaluated.
Results Reactogenicity was absent in the majority of participants, with mild events. The majority of adverse events were mild and were resolved. One serious adverse event was reported, which was found to be unrelated to vaccination. All three vaccine formulations resulted in robust immune responses comparable to a panel of convalescent serum. No significant differences were observed between the 3-μg and 6-μg Algel-IMDG groups. Neutralizing responses to homologous and heterologous SARS-CoV-2 strains were detected in all vaccinated individuals. Cell-mediated responses were biased to a Th-1 phenotype.
Conclusions BBV152 induced binding and neutralising antibody responses and with the inclusion of the Algel-IMDG adjuvant, this is the first inactivated SARS-CoV-2 vaccine that has been reported to induce a Th1-biased response. Vaccine induced neutralizing antibody titers were reported with two divergent SARS-CoV-2 strains. BBV152 is stored between 2°C and 8°C, which is compatible with all national immunization program cold chain requirements. Both Algel-IMDG formulations were selected for the phase 2 immunogenicity trials. Further efficacy trials are underway.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04471519
Funding Statement
This study was funded by Bharat Biotech.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the National Regulatory Authority (India) and the respective Ethics Committees and was conducted in compliance with all International Council for Harmonization (ICH) Good Clinical Practice guidelines. Full names and affiliations of each Ethics Committee members were not disclosed to the Sponsor. Ethics Committees Approval Site Name, Reference Number Nizams Institute of Medical Science, Hyderabad, Telangana, ECR/303/INST/AP/2013/RR-19 All India Institute of Medical Science, New DelhiECR/547/INST/DL/2014/RR-17 PGIMS, Rohtak, HaryanaECR/293/Inst/HR/2013/RR-19 All India Institute of Medical Science, PatnaECR/1387/INST/BR/2020 Redkar Hospital/Research Centre, GoaECR/902/INST/GA/2018 IMS/SUM Hospital, OdishaECR/627/INST/OR/2014/RR-17 Jeevan Rekha Hospital, Belgaum, KarnatakaECR/1242/INST/KA/2019 Gillukar Multispeciality Hospital, NagpurECR/1374/INST/MH/2020 Rana Hospital and Trauma Center, Gorakhpur, Uttar PradeshECR/1332/INST/UP/2020 Prakhar Hospital, Kanpur, Utter PradeshECR/1017/INST/UP/2017 SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu, ECR/431/INST/TL/2013/RR-19
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This is an interim report of an ongoing clinical trial. This report was prespecified in the protocol.
